IP Library Granted Patent US 7,582,752
Granted Patent B2
US 7,582,752 · App. 10/580,621 · Granted Sep 1, 2009

Process for the resolution of nefopam

Assignee: Sosei R&D Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,582,752
App. No.
10/580,621
Granted
Sep 1, 2009
Kind
B2
Abstract

A process for increasing the optical purity of a mixture of enantiomers of nefopam uses a substantially single enantiomer of a O,O-diaroyltartaric acid as a resolving agent, via a bisnefopam salt of the acid. This salt is new.

Claims (11)

1. A process for increasing the optical purity of a mixture of enantiomers of nefopam by using a substantially single enantiomer of a O,O-diaroyltartaric acid as a resolving agent, via a bisnefopam salt of the acid.

2. The process according to claim 1 , for preparing a substantially single enantiomer of nefopam by means of resolution of racemic nefopam.

3. The process according to claim 1 , for preparing a substantially single enantiomer of nefopam, which comprises reverse resolution of racemic nefopam, using sequentially a single enantiomer of a O,O-dibenzoyltartaric acid and men the other enantiomer.

4. The process according to claim 1 , for preparing substantially single enantiomer (+)-nefopam, which uses O,O-dibenzoyl-L-tartaric acid as the resolving agent.

5. The process according to claim 1 , for preparing substantially single enantiomer (−)-nefopam, which uses O,O-dibenzoyl-D-tartaric acid as the resolving agent.

6. The process according to claim 1 , which is conducted in a solvent selected from alcohols, esters, ketones and halogenated solvents.

7. The process according to claim 1 , which comprises the further step of conversion of the salt obtained by the resolution to the free base form of nefopam or a pharmaceutically acceptable salt thereof.

8. The process according to claim 1 , wherein the amount of the resolving agent is less than 1 equivalent.

9. The process according to claim 8 , wherein said amount is no more than 0.5 equivalent.

10. A bisnefopam salt of a substantially single enantiomer of a O,O-diaroyltartaric acid.

11. The salt according to claim 10 , wherein the acid is O,O-dibenzoyltartaric acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2007
From: HARRIS, MICHAEL CHRISTOPHER JAMES; BROWN, STUART
To: ARAKIS LTD
Reel/Frame 019061/0607 →
CHANGE OF NAME Recorded Jan 31, 2007
From: ARAKIS LIMITED
To: SOSEI R&D LTD.
Reel/Frame 018826/0339 →
Priority Claims (1)
GB 0328871.9 · Dec 12, 2003 · national
Continuity (1)
Related Publication 20070276137A1 · Nov 29, 2007